{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:15:47Z","timestamp":1778944547641,"version":"3.51.4"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Peripheral T cell lymphoma (PTCL) is a rare and aggressive type of non-Hodgkin\u2019s lymphoma that affects mature T cells. This type of cancer is characterized by the abnormal growth of T cells, which can accumulate in the lymph nodes, spleen, bone marrow, and other organs, leading to a variety of symptoms. PTCLs are often difficult to diagnose and treat, and they have a poorer prognosis than other types of lymphoma. However, recent advancements in treatment options, such as targeted therapies have shown promise in improving outcomes for patients with PTCL. Here, we discuss the use of autologous and allogeneic hematopoietic cell transplantation (HCT) as a treatment strategy for patients with PTCL, as well as the recent treatment approaches based on advanced cellular therapy. The current evidence for the use of HCT in PTCL is mainly derived from registry data, retrospective studies, and expert opinion, as randomized trials are limited due to the low incidence and histological heterogeneity of PTCL subtypes.<\/jats:p>","DOI":"10.3389\/fonc.2023.1195759","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T05:45:41Z","timestamp":1693460741000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Autologous, allogeneic hematopoietic cell transplantation and CAR-T\/NK therapy: what is their real importance in PTCL?"],"prefix":"10.3389","volume":"13","author":[{"given":"Samuel C. F.","family":"Couto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Kowes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila S.","family":"Aurabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo G. M.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Hematologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of hamatolymphoid tumors: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00590-5","article-title":"Hematopoietic cell transplantation and adoptive cell therapy in peripheral T cell lymphoma","volume":"15","author":"Rogers","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey","volume":"33","author":"Jantunen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24372","article-title":"Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas","volume":"91","author":"Yam","year":"2016","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral t-cell lymphomas: Results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group","volume":"79","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"D\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodr\u00edguez","year":"2003","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.04.021","article-title":"Outcome of allogeneic and autologous hematopoietic cell transplantation for high-risk peripheral T cell lymphomas: a retrospective analysis from a Chinese center","volume":"23","author":"Huang","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3288-7","article-title":"The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience","volume":"97","author":"Rohlfing","year":"2018","journal-title":"Ann Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.07.003","article-title":"Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin\u2019s lymphoma","volume":"19","author":"Czajczynska","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0360-9","article-title":"Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease","volume":"54","author":"Wulf","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08210.x","article-title":"Allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas","volume":"150","author":"Shustov","year":"2010","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq698","article-title":"A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.004","article-title":"Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphomas as front-line consolidation or in the relapsed\/refractory setting: A systematic review\/meta-analysis","volume":"22","author":"El-Asmar","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0294-2","article-title":"High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI\/Cancer Research UK Phase II Study","volume":"54","author":"Phillips","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT","volume":"121","author":"Jantunen","year":"2013","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23992","article-title":"Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort","volume":"90","author":"Nijeboer","year":"2015","journal-title":"Am J Hematol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.1038\/bcj.2015.43","article-title":"Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma","volume":"5","author":"Rashidi","year":"2015","journal-title":"Blood Cancer J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25674","article-title":"Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas","volume":"95","author":"Foss","year":"2020","journal-title":"Am J Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1563691","article-title":"Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis","volume":"8","author":"Al-Mansour","year":"2019","journal-title":"Leukemia Lymphoma 60"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003971","article-title":"Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2","volume":"6","author":"Savage","year":"2022","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008825","article-title":"A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"19","author":"Schmitz","year":"2020","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.07.027","article-title":"Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American society for blood and ma","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/ajh.24992","article-title":"Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL)","volume":"93","author":"Zhang","year":"2018","journal-title":"Am J Hematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/bmt.2011.16","article-title":"Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine\u2013melphalan conditioning for treatment of mature T-cell lymphomas","volume":"47","author":"Delioukina","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0696-z","article-title":"Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: A CIBMTR analysis","volume":"12","author":"Epperla","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e219807","DOI":"10.1001\/jamanetworkopen.2021.9807","article-title":"Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma","volume":"4","author":"Du","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/1535370215584936","article-title":"From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy","volume":"240","author":"Firor","year":"2015","journal-title":"Exp Biol Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid Malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2019.06.007","article-title":"Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studies","volume":"42","author":"Pican\u00e7o-Castro","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"key":"B46","unstructured":"SvobodaJ\n            RheingoldSR\n            GillSI\n            GruppSA\n            LaceySF\n            KulikovskayaI\n          Brief Report CLINICAL TRIALS AND OBSERVATIONS Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma2018"},{"key":"B47","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/gt.2008.189","article-title":"Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer","volume":"16","author":"Birkholz","year":"2009","journal-title":"Gene Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.070","article-title":"Treatment of advanced leukemia in mice with mRNA engineered T cells","volume":"22","author":"Barrett","year":"2011","journal-title":"Hum Gene Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy A bs t r ac t","volume":"365","author":"Stasi","year":"2011","journal-title":"N Eng J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/CCO.0000000000000243","article-title":"Tumor microenvironment in mycosis fungoides and S\u00e9zary syndrome","volume":"28","author":"Gonzalez","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0270","article-title":"Primary t cells from cutaneous t-cell lymphoma skin explants display an exhausted immune checkpoint profile","volume":"6","author":"Querfeld","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1420936111","article-title":"Molecular architecture of the \u03b1\u03b2 T cell receptor-CD3 complex","volume":"111","author":"Birnbaum","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell Malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell Malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic Malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.5045\/br.2020.55.1.10","article-title":"A general view of CD33+ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy","volume":"55","author":"Fathi","year":"2020","journal-title":"Blood Res"},{"key":"B57","doi-asserted-by":"crossref","unstructured":"JamalS\n            PickerLJ\n            AquinoDB\n            McKennaRW\n            Brian DawsonD\n            KroftSH\n          Immunophenotypic Analysis of Peripheral T-Cell Neoplasms A Multiparameter Flow Cytometric Approach2001","DOI":"10.1309\/QF6N-VAQW-N74H-4JE2"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell Malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2020.12.026","article-title":"The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches","volume":"84","author":"Weiner","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2929-6","article-title":"Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab)","volume":"96","author":"Shen","year":"2017","journal-title":"Ann Hematol"},{"key":"B61","doi-asserted-by":"crossref","unstructured":"PinzKG\n            YakaboskiE\n            JaresA\n            LiuH\n            FirorAE\n            ChenKH\n          Targeting T-cell Malignancies using anti-CD4 CAR NK-92 cells2017","DOI":"10.18632\/oncotarget.22626"},{"key":"B62","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ajh.24794","article-title":"Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell Malignancies","volume":"92","author":"Perera","year":"2017","journal-title":"Am J Hematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell Malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014498","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99442","article-title":"TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy","volume":"3","author":"Rasaiyaah","year":"2018","journal-title":"JCI Insight"},{"key":"B68","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ymthe.2019.10.001","article-title":"Simultaneous deletion of endogenous TCR\u03b1\u03b2 for TCR gene therapy creates an improved and safe cellular therapeutic","volume":"28","author":"Morton","year":"2020","journal-title":"Mol Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell Malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"Oncoimmunology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological Malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/nejmoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","author":"Chiesa","year":"2023","journal-title":"New Engl J Med"},{"key":"B72","doi-asserted-by":"crossref","unstructured":"KruschinskiA\n            MoosmannA\n            PoschkeI\n            NorellH\n            ChmielewskiM\n            SeligerB\n          Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas2008","DOI":"10.1073\/pnas.0804788105"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2810","article-title":"2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells","volume":"15","author":"Altvater","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.671519","article-title":"A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell Malignancies","volume":"14","author":"Shimasaki","year":"2012","journal-title":"Cytotherapy"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"New Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front Pharmacol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00465","article-title":"Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation","volume":"8","author":"Simonetta","year":"2017","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new car-based therapies with a focus on car nk cells: What lies beyond car-engineered t cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discovery"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell Malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"B86","doi-asserted-by":"crossref","unstructured":"ChenKH\n            WadaM\n            FirorAE\n            PinzKG\n            JaresA\n            LiuH\n          Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell Malignancies2016","DOI":"10.18632\/oncotarget.11019"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0732-7","article-title":"2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell Malignancies","volume":"12","author":"Xu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.101","article-title":"\u03b3\u03b4 T cells in homeostasis and host defence of epithelial barrier tissues","volume":"17","author":"Nielsen","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00985","article-title":"Human \u03b3\u03b4 T-cell control of mucosal immunity and inflammation","volume":"9","author":"McCarthy","year":"2018","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3539-3","article-title":"RNA-transfection of \u03b3\/\u03b4 T cells with a chimeric antigen receptor or an \u03b1\/\u03b2 T-cell receptor: A safer alternative to genetically engineered \u03b1\/\u03b2 T cells for the immunotherapy of melanoma","volume":"17","author":"Harrer","year":"2017","journal-title":"BMC Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol Ther"},{"key":"B92","doi-asserted-by":"publisher","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-specific T cells for the immunocompromised patient","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23594","article-title":"Going both ways: immune regulation via D1d-dependent NKT cells","volume":"114","author":"Godfrey","year":"2004","journal-title":"J Clin Invest"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.3.1171","article-title":"An invariant Va24-JaQ\/Vb11 T Cell Receptor is expressed in all individuals in clonally expanded CD4-8- T cells","volume":"180","author":"Dellabona","year":"1994","journal-title":"J Exp Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1118681","article-title":"CAR-iNKT cells targeting clonal TCRVb chains as a precise strategy to treat T cell lymphoma","author":"Rowan","year":"2023","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1074-2","article-title":"AntiGD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: An interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.944511","article-title":"A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"B101","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume-title":"Blood","author":"Weisenburger","year":"2011"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"key":"B104","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumor heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113125","article-title":"Role of hematopoietic stem cell transplantation in peripheral T-cell lymphoma","volume":"12","author":"Abeyakoon","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.784421","article-title":"Myeloid immune cells CARrying a new weapon against cancer","volume":"9","author":"Ramos","year":"2021","journal-title":"Front Cell Dev Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1195759\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T05:45:45Z","timestamp":1693460745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1195759\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":107,"alternative-id":["10.3389\/fonc.2023.1195759"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1195759","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]},"article-number":"1195759"}}